ProfileGDS5678 / 1422511_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 89% 89% 91% 88% 89% 89% 88% 88% 87% 89% 88% 89% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.8766288
GSM967853U87-EV human glioblastoma xenograft - Control 27.0590289
GSM967854U87-EV human glioblastoma xenograft - Control 37.0412789
GSM967855U87-EV human glioblastoma xenograft - Control 47.5853891
GSM967856U87-EV human glioblastoma xenograft - Control 56.9364488
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.8483189
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.9114689
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.8223788
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.8919388
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.7616887
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.9356789
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.9950588
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.0333889
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.8459188